HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Sangamo Therapeutics (NASDAQ:SGMO) and maintained a $3 price target on the stock.
February 06, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirmed a Buy rating on Sangamo Therapeutics with a $3 price target.
The reiteration of a Buy rating and maintenance of a $3 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors about Sangamo Therapeutics' potential, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100